3/24/2014 | BK | Bausch & Lomb loans pulled from Markit LCDX after dealer poll
|
9/20/2013 | HYLM | Bausch & Lomb calls full $350 million of 9 7/8% notes due 2015
|
5/28/2013 | BKCVHY | Moody's might upgrade Bausch
|
4/25/2013 | BK | Market Commentary: Dole, Nuveen, Lineage Logistics, Bausch & Lomb, CDW, Truven, Wabash, CCM Merger break
|
4/22/2013 | BK | Market Commentary: Delta, U.S. Shipping, Osmose, EveryWare, Advantage Sales break; Lineage, Caraustar up deadlines
|
4/10/2013 | BK | Bausch & Lomb launches $3.08 billion credit facility repricing
|
4/10/2013 | BK | Market Commentary: First Data, Charter Communications, Surgery Center, Utex, Steward Health hit secondary
|
4/9/2013 | BK | Bausch & Lomb readies credit facility lender call for Wednesday
|
3/25/2013 | BKCVHY | S&P lifts Bausch & Lomb view to positive
|
8/20/2012 | HYLM | Bausch + Lomb gets tenders for $74.69 million 9 7/8% notes due 2015
|
8/6/2012 | BK | Bausch + Lomb to draw down delayed-draw term loan to fund tender offer
|
8/6/2012 | HYLM | Bausch + Lomb extends early tender date for 9 7/8% notes due 2015
|
6/6/2012 | BK | Market Commentary: Data Device, Pelican Products break; Chesapeake up on asset sale buzz; Lee Enterprises rises
|
5/17/2012 | BK | Bausch & Lomb sells $400 million delayed-draw loan at discount of 99
|
5/17/2012 | BK | Market Commentary: Momentive, U.S. Foodservice lower; Misys revises deadline; Lord & Taylor cancels repricing
|
5/14/2012 | BK | Bausch & Lomb begins marketing of $400 million delayed-draw loan
|
5/14/2012 | BK | Market Commentary: Arch Coal frees up; Bausch & Lomb launches delayed-draw syndication; Jazz reveals timing
|
5/10/2012 | BK | Bausch & Lomb reduces U.S. term loan B size to $1.935 billion
|
5/10/2012 | BK | Market Commentary: Bausch & Lomb, Harbor Freight, Burlington free up; Taminco, Brickman update pricing
|
5/4/2012 | BK | Market Commentary: Affinity Gaming, Sophos, 4L Holdings break; Emerald Performance, Evertec tweak deals
|
5/2/2012 | BK | Bausch & Lomb ups spread on U.S. term loan B to Libor plus 425 bps
|
5/2/2012 | BK | Market Commentary: Wabash, Osmose break; First Data inches up; Bausch & Lomb, Sophos, MSCI rework deals
|
4/19/2012 | BK | Market Commentary: Landry's, Formula One, Endurance, MotorCity break; Plato reworks loan; Wendy's sets coupon
|
4/19/2012 | BKCVHY | Moody's rates Bausch & Lomb facilities B1
|
4/19/2012 | BKCVHY | S&P: Bausch & Lomb loan B+
|
4/19/2012 | BK | Bausch & Lomb discloses term loan pricing guidance with launch
|
4/16/2012 | BK | Bausch & Lomb to launch $3.485 billion credit facility on Thursday
|
4/16/2012 | BK | Market Commentary: Goodyear second-lien breaks; Press Ganey revises tranching; HCA, PRV Aerospace set talk
|
3/28/2012 | BKCVHY | Moody's: Deal is negative for Bausch & Lomb
|
3/27/2012 | BK | Bausch & Lomb plans $350 million incremental term loan
|
9/9/2011 | BKCVHY | Moody's: No changes for Bausch & Lomb
|
4/13/2010 | BKCVHY | Moody's ups Bausch & Lomb outlook to stable
|
2/5/2010 | HY | Market Commentary: Downsized Media General prices; market retreats as stocks gyrate but new deals mostly hang in
|
6/19/2009 | BKHY | S&P affirms Bausch & Lomb
|
5/12/2009 | HY | Market Commentary: Upsized Calpine, Linn price; Cellu Tissue, Gibson slate deals; Lear lifted, Sprint struggles
|
4/1/2009 | BKCVHY | Moody's: Bausch & Lomb outlook negative
|
3/26/2009 | BK | Market Commentary: Bausch & Lomb softens on numbers; Visteon shrugs off ratings cut; LCDX, cash trade up
|
10/26/2007 | BK | Market Commentary: FHC Health Systems sets talk; NV Broadcasting, HD Supply break; Tousa heads lower
|
10/26/2007 | CVHY | Bausch & Lomb completes tender for 6.95%, 5.9%, 6.56%, 7 1/8% notes, convertible floaters
|
10/26/2007 | SS | Bausch & Lomb acquisition complete, stock ceases trading
|
10/22/2007 | HY | Market Commentary: Ceridian deal hits the road; TXU price talk emerges; secondary rebounds after initial weakness
|
10/22/2007 | BK | Market Commentary: Bausch breaks; Texas Competitive adds MFN to B-3; NV tweaks deal; CCS sets talk; Deerfield canceled
|
10/18/2007 | HY | Bausch & Lomb prolongs tender for 6.95%, 5.9%, 6.56%, 7 1/8% notes
|
10/17/2007 | BK | Market Commentary: Bausch & Lomb trims OIDs; Nuveen sets talk; Cablevision falls on buyout opposition; LCDX lower
|
10/17/2007 | HY | Market Commentary: Spectrum, Bon-Ton, GMAC trade lower; Cablevision up as buyout jeopardized; USIS price talk emerges
|
10/16/2007 | HY | Market Commentary: First Data mega-deal prices, Bausch & Lomb too; Movie Gallery off on Chapter 11; GM bounces around
|
10/16/2007 | HY | New Issue: Bausch & Lomb sells $650 million eight-year notes to yield 9.92%
|
10/15/2007 | BK | Market Commentary: Texas Competitive sets OID on B-2 tranche; Bausch upsizes; PRA fills out; Telesat breaks
|
10/15/2007 | BKSS | Bausch & Lomb increases U.S. term loan size by $100 million
|
10/15/2007 | HY | Bausch & Lomb downsized, restructured $650 million eight-year notes talked at 10% area
|
10/15/2007 | HY | Market Commentary: Bausch & Lomb downsizes, restructures deal; Level 3 off on CFO departure; GM gyrates
|
10/12/2007 | BK | Market Commentary: TXU sees positive momentum; Allison wraps sell down; Flextronics, GSI break; LCDX stronger
|
10/12/2007 | HY | Market Commentary: Allison Transmission prices another new deal; GM continues rise; Trump gains, housing eases
|
10/5/2007 | BKCVHY | Moody's rates Bausch & Lomb loans B1, notes Caa1
|
10/5/2007 | HY | Market Commentary: Cash market, index unchanged in low volume; GM lower with Treasuries; new corporate paper holds in
|
10/4/2007 | BKCVHY | S&P cuts Bausch & Lomb, rates loans BB-, notes B-
|
10/4/2007 | HY | Bausch & Lomb gets needed consents for 6.95%, 5.9%, 6.56%, 7 1/8% notes
|
10/3/2007 | HY | Bausch & Lomb to start roadshow Tuesday for $750 million three-part note offering
|
10/3/2007 | HY | Market Commentary: Ryerson prices two-part offering; Canadian forest product names up; Pogo up on M&A developments
|
10/1/2007 | BK | Market Commentary: Bausch & Lomb, NV Broadcasting, PRA set talk; Flextronics firms OIDs; LCDX trades up
|
10/1/2007 | HY | Bausch & Lomb details $750 million three-part notes offering
|
9/28/2007 | BK | Market Commentary: First Data term loan seen stabilizing; LandSource loan up 5 points; LCDX down 0.35
|
9/28/2007 | BKSS | Bausch & Lomb sets Monday bank meeting for $2.6 billion credit facilities
|
9/24/2007 | BK | Bausch & Lomb reveals more structural details on $2.6 billion facility
|
9/21/2007 | SS | Market Commentary: Harman drops nearly 25% as sponsors try to pull LBO; Genesco sues Finish Line to press closure
|
9/21/2007 | BKCVHY | S&P keeps Bausch & Lomb on watch
|
9/21/2007 | SS | Bausch & Lomb holders OK merger with Warburg Pincus affiliates
|
9/19/2007 | CVHY | Bausch & Lomb tenders for six series of notes, convertibles
|
8/3/2007 | SS | Bausch & Lomb sets meeting day for merger vote
|
8/1/2007 | SS | Advanced Medical Optics drops bid for Bausch & Lomb
|
7/31/2007 | SS | Advanced Medical Optics says it needs more time to provide Bausch & Lomb with requested information
|
7/30/2007 | SS | Bausch & Lomb OKs discussions with Advanced Medical Optics, still firm on Warburg Pincus deal
|
7/27/2007 | SS | Advanced Medical Optics to amend proposal for Bausch & Lomb to show proof of shareholder support
|
7/26/2007 | SS | Sandell questions actions of Bausch & Lomb special committee, will vote against Warburg Pincus offer
|
7/24/2007 | SS | Bausch & Lomb: Without additional assurances, Advanced Medical Optics proposal may not be superior
|
7/12/2007 | SS | SAC Capital reduces stake in Bausch & Lomb
|
7/12/2007 | SS | Advanced Medical Optics says ValueAct's objections based on inaccurate, misleading information
|
7/11/2007 | SS | ValueAct against Advanced Medical Optics' bid for Bausch & Lomb
|
7/10/2007 | BKCVHY | S&P: Bausch & Lomb remains on watch
|
7/10/2007 | BKHY | Bausch to get $2.6 billion credit facility, $1.05 billion bonds for buyout by Warburg
|
7/10/2007 | CVHY | Bausch & Lomb to tender for notes if Warburg Pincus merger proceeds
|
7/6/2007 | CV | Market Commentary: All eyes on Bausch & Lomb, Advanced Medical Optics; Huntsman up again; Hilton flattens
|
7/6/2007 | SS | Advanced Medical Optics confirms $75 per share bid to acquire Bausch & Lomb
|
7/6/2007 | SS | Market Commentary: H&R Block soft; Bausch & Lomb, Advanced Medical weak; Macy's, Dillard's higher; Sterling rises
|
7/5/2007 | SS | SAC buys 5.5% stake in Bausch & Lomb
|
6/26/2007 | CV | Market Commentary: Gannett jumbo deal, GSI issue on tap; Huntsman surges on merger; Amgen slides; Medtronic rises
|
6/8/2007 | CV | Market Commentary: Bausch & Lomb unmoved by fading hopes of rival offer; Amgen, Intel, Ford recover; market still cautious
|
6/4/2007 | SS | Market Commentary: Doral gets rival bid; Accredited deal pushes Novastar; Cadence climbs; Solectron drives Sanmina
|
5/29/2007 | CV | Market Commentary: Archstone trims hedges; Advanced Medical, Bausch & Lomb fall on recall; NII, Luminent plans deals
|
5/29/2007 | SS | Market Commentary: Archstone, URS, Washington surge on buyouts; Advanced Medical, Bausch & Lomb suffer recall pains
|
5/25/2007 | CV | Market Commentary: GM roars ahead; Archstone-Smith gains, Bausch & Lomb up, Advanced Medical quiet on takeover talk
|
5/24/2007 | SS | Market Commentary: Advanced Medical Optics eyes Bausch & Lomb bid race; Topps gets rival bid; nerves sink metals
|
5/24/2007 | CV | Market Commentary: Bausch & Lomb quiet on bidding event, Advanced Medical Optics slides; GM slightly higher in gray
|
5/17/2007 | CV | Market Commentary: Countrywide improves on debut; Bausch & Lomb calms down from buyout fever; Micron gains in gray
|
5/16/2007 | CV | Market Commentary: Bausch & Lomb gains on buyout; CV Therapeutics keeps rising; Countrywide, Micron launch giant deals
|
5/16/2007 | SS | Warburg Pincus to acquire Bausch & Lomb in transaction valued at $4.5 billion
|
5/16/2007 | BK | Bausch & Lomb gets debt financing commitment for buyout by Warburg Pincus
|
5/16/2007 | SS | Market Commentary: Bausch & Lomb rises; Quanex surges; Riviera up; WCI lifted; InterContinental Hotel higher
|
5/16/2007 | BKCVHY | S&P lowers Bausch & Lomb
|
5/16/2007 | BKCVHY | Moody's keeps Bausch & Lomb on review
|
5/16/2007 | BKCVHY | Fitch keeps Bausch & Lomb on watch
|
4/23/2007 | CV | Market Commentary: MedImmune surges on buyout; Bausch & Lomb climbs on rumors; AMD, Charming Shoppes launch deals
|
3/6/2007 | CV | Market Commentary: Bausch & Lomb gains; DexCom quiet on debut; Barnes absent in gray; Cypress, Developers launch deals
|
2/7/2007 | CV | Bausch & Lomb seeks extends solicitation for notes due 2023
|
2/2/2007 | BKCVHY | Moody's cuts Bausch & Lomb to junk
|
1/31/2007 | BK | Bausch & Lomb gets extension of loan waiver
|
1/31/2007 | CV | Bausch & Lomb seeks consents to amend notes including convertibles due 2023
|
11/13/2006 | BT | Bear Stearns has Bausch & Lomb at peer perform
|
11/10/2006 | BKBTCV | S&P: Bausch & Lomb unaffected
|
10/16/2006 | CV | Market Commentary: Open Solutions soars on buyout; Bausch and Lomb, Wyeth slip on rate fears; SanDisk gains on outlook
|
9/29/2006 | BTCV | Bausch & Lomb obtains needed consents for six notes series
|
9/28/2006 | BTCV | Bausch & Lomb prolongs consent solicitation for 7 1/8% debentures, receives consents for other notes
|
9/18/2006 | BT | Bausch & Lomb licenses Segra compound from Schering
|
8/31/2006 | BT | Bausch & Lomb gets extension of waiver regarding any potential defaults
|
8/29/2006 | BT | Bausch & Lomb licenses rPlasmin from Talecris
|
8/8/2006 | CV | Market Commentary: McData gains with offer; Teva rides earnings boost; Scottish Re firms as put stays; Charter slips on loss
|
5/22/2006 | CV | Bausch gets required consents for 7.125% debentures, other notes, convertibles
|
5/17/2006 | CV | Bausch extends consent solicitation for 7.125% debentures, gets consents for other notes, convertibles
|
5/15/2006 | BT | Market Commentary: BioMimetic goes south; Sirna off on new deal; Cambridge rockets on buyout; Threshold extends fall
|
5/15/2006 | CV | Market Commentary: Bausch and Lomb gains on product recall; FEI prices $100 million deal within talk
|
5/12/2006 | BTCV | Fitch downgrades Bausch & Lomb
|
5/4/2006 | BT | Market Commentary: Bausch & Lomb stock sinks after buyback offering to avoid default; ImmunoGen stock up on earnings
|
5/4/2006 | CV | Market Commentary: Bausch and Lomb up dollar-neutral on debt tenders; JDS Uniphase falls outright on poor guidance
|
5/3/2006 | CV | Bausch & Lomb to solicit consents for convertibles
|
4/24/2006 | CV | Market Commentary: Bausch and Lomb, Schlumberger get analysts' thumbs up; Halliburton, Medtronic shrug off reports
|
4/21/2006 | CV | Market Commentary: Mercury Interactive gains on waiver consent offer; Vitesse marked lower on delayed filings
|
4/13/2006 | CV | Market Commentary: Medtronic gains dollar-neutral on debut; Bausch and Lomb rebounds before product pulled
|
4/12/2006 | CV | Market Commentary: Bausch and Lomb firms against falling stock; Cypress rebounds as Synaptics flattens; Rentech debut quiet
|
4/12/2006 | BTCVHY | Fitch puts Bausch & Lomb on negative watch
|
4/12/2006 | BTCVHY | Moody's keeps Bausch & Lomb on review for downgrade
|
4/11/2006 | BT | Bear Stearns rates Bausch & Lomb at peer perform
|
4/11/2006 | BTCVHY | S&P cuts Bausch & Lomb outlook to negative
|
4/11/2006 | CV | Market Commentary: Bausch and Lomb wider on product scare; Synaptics gains on iPod rumors; Medtronic plans $4 billion deal
|
4/5/2006 | BT | Bausch & Lomb lowered to peer perform by Bear Stearns
|
4/3/2006 | BT | Credit Suisse puts Bausch & Lomb at underperform
|
4/3/2006 | BT | pSivida, Bausch & Lomb study shows Retisert implant slows progression of diabetic retinopathy
|
3/23/2006 | BTCVHY | Moody's may cut Bausch & Lomb
|
3/17/2006 | BTCV | S&P: Bausch & Lomb unchanged
|
2/9/2006 | BT | Bausch & Lomb, Novartis to co-promote Retisert
|
12/23/2005 | BT | Market Commentary: Progenics, Wyeth rise on $416.5 million pact; Par Pharma higher; AtheroGenics gains further 7%
|
12/1/2005 | BT | Bausch & Lomb signs license, research deals with Cephalon, PTC to develop treatments for blinding conditions
|
7/5/2005 | BT | Market Commentary: Voyager plans IPO; Able Labs plunges; Mylan Labs launch seen; Boston Scientific up, J&J lower
|
5/10/2005 | CV | Moody's pulls Bausch & Lomb from junk
|
4/8/2005 | CV | S&P raises Bausch & Lomb
|
2/17/2005 | CV | Fitch rates Bausch & Lomb BBB
|
2/7/2005 | CV | Moody's: Bausch & Lomb up to positive
|
12/17/2004 | CV | S&P rates Bausch & Lomb convertibles BBB-
|
12/15/2004 | CV | Bausch & Lomb exchanges 98.6% of convertibles
|
11/15/2004 | CV | S&P: Bausch & Lomb unaffected
|
11/15/2004 | CV | Bausch & Lomb starts exchange for convertibles
|
9/24/2004 | CV | Market Commentary: Calpine new issue trade seen awkward; Dobson off on buy; PMA Capital exchange seen
|
7/2/2004 | CV | S&P: Bausch & Lomb unaffected
|
5/28/2004 | CV | S&P: Bausch & Lomb stable
|
1/29/2004 | CV | Market Commentary: Wyeth, Sallie Mae, Lockheed floaters see demand; hedgies hurt by premium contractions
|
7/30/2003 | CV | Market Commentary: ExpressJet in holding pattern, waiting on Continental signal; three other new deals emerge
|
7/29/2003 | CV | Market Commentary: ExpressJet soars in gray market, as do most of new issues in play; Nextel Partners, Dynegy emerge
|
7/29/2003 | CV | New Issue: Bausch & Lomb $140 million cash-to-zero convertible pays 6-mo Libor+50 bps, up 50%
|
7/29/2003 | CV | S&P rates Bausch & Lomb at BBB-
|
7/28/2003 | CV | Bausch & Lomb $140 million cash-to-zero floaters talked at 6-mo Libor plus 15-65 bps, up 48-52%
|
7/28/2003 | CV | Market Commentary: Dynegy seen launching smaller convert early Tuesday; seven other deals launched Monday
|
11/18/2002 | HY | Market Commentary: UAL bid up on further belt-tightening; NDC upsizes 10-year deal
|
11/18/2002 | HY | New Issue: Bausch & Lomb five-B deal generates significant high yield participation
|
3/11/2002 | HY | Moody's lowers Preem outlook to negative
|
1/28/2002 | HY | Moody's rates UCAR's planned notes B2, raises outlook
|